|
1) American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000; 161: 646-64
|
|
|
|
2) American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002; 165: 277-304
|
|
|
|
|
|
3) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会, 編. In: 特発性間質性肺炎診断と治療の手引き. 東京: 南江堂; 2004
|
|
|
|
|
|
4) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会, 編. In: 特発性間質性肺炎診断と治療の手引き改定第2版. 東京: 南江堂; 2011
|
|
|
|
|
|
5) Raghu G, Collard HR, Ebina M, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183: 788-824
|
|
|
|
|
6) Collard HR, Moore BB, Flaherty KR, et al; Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007; 176: 636–643
|
|
|
|
|
|
7) Schunemann HJ, Jaeschke R, Cook DJ, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med. 2006; 174: 605-14
|
|
|
|
|
|
8) Taniguchi H, Ebina M, Kondoh Y, et al; Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis: A phase III clinical trial in Japan. Eur Respir J. 2010; 35: 821-9
|
|
|
|
|
|
9) Noble PW, Albera C, Bradford WZ, et al; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377: 1760-9
|
|
|
|
|